Skip to content
10-K

Annual Report

AN2 Therapeutics, Inc. ANTX

0001193125-26-110693

← back to feed
Filed
Mar 17, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 10, 2026 35.94M sh
Shares Diluted FY 2025 · Dec 31, 2025 30.22M sh
Shares Diluted FY 2025 · Dec 31, 2024 29.83M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$29.83M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$49.26M
Cash And Equivalents FY 2025 · Dec 31, 2025 $19.94M
Cash And Equivalents FY 2025 · Dec 31, 2024 $21.35M
Stockholders Equity FY 2025 · Dec 31, 2025 $53.06M
Stockholders Equity FY 2025 · Dec 31, 2024 $81.85M
Stockholders Equity FY 2025 · Dec 31, 2023 $124.7M
Current Liabilities FY 2025 · Dec 31, 2025 $8.72M
Current Liabilities FY 2025 · Dec 31, 2024 $10.24M
Total Liabilities FY 2025 · Dec 31, 2025 $8.89M
Total Liabilities FY 2025 · Dec 31, 2024 $10.24M
Current Assets FY 2025 · Dec 31, 2025 $59.94M
Current Assets FY 2025 · Dec 31, 2024 $86.26M
Total Assets FY 2025 · Dec 31, 2025 $61.95M
Total Assets FY 2025 · Dec 31, 2024 $92.09M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.16
Eps Diluted FY 2025 · Dec 31, 2024 −$1.72
Eps Basic FY 2025 · Dec 31, 2025 −$1.16
Eps Basic FY 2025 · Dec 31, 2024 −$1.72
Sga Expense FY 2025 · Dec 31, 2025 $13.34M
Sga Expense FY 2025 · Dec 31, 2024 $14.07M
Rd Expense FY 2025 · Dec 31, 2025 $24.77M
Rd Expense FY 2025 · Dec 31, 2024 $40.49M
Net Income FY 2025 · Dec 31, 2025 −$35.17M
Net Income FY 2025 · Dec 31, 2024 −$51.32M
Operating Income FY 2025 · Dec 31, 2025 −$38.11M
Operating Income FY 2025 · Dec 31, 2024 −$56.79M